Background: This study monitored the viral content of the Novel Oral Polio Vaccine Type 2 (nOPV2) and VVM degradation during storage at different temperatures over a specified period. Method: Weekly vaccine titers were obtained until the vaccine vial monitor (VVM) degraded to 100%, except when stored in a refrigerator. Results: At refrigerator temperature, 90% and 10% of the vaccine vials retained potency for six and seven months, respectively, but none retained potency at 8 to 9 months. The median survival time was approximately seven months. The VVM remained at 0% degradation up to 4 months and changed to 5%, 10%, 20%, 30%, and 40% after 5, 6,7,8 and nine months, respectively. At room temperature, the nOPV2 retained potency during the first two weeks, declined by the third week, and none retained potency by the fourth week. The degradation of the VVM was rated 10 %, 30%, 60%, and 100% after one, two, three, and four weeks of storage, respectively. The median survival time at incubator temperature was one week, during which 10% and 90% of the vaccine in batches 2 and 1, respectively, survived, but all vials reached 0.0% at week 3. At atmospheric temperature, the survival probability was zero within a week of exposure. Time accounted for over 80% of the variation in vaccine titer. Conclusion: The potency of the nOPV2 was preserved under refrigeration for seven months, at room temperature for two weeks, in an incubator for a week, and severely degraded at atmospheric temperatures within a week.